Focused update: Guidelines of care for the management of actinic keratosis
Author:
Funder
American Academy of Dermatology
Publisher
Elsevier BV
Subject
Dermatology
Reference8 articles.
1. The burden of skin disease in the United States;Lim;J Am Acad Dermatol,2017
2. Guidelines of care for the management of actinic keratosis;Eisen;J Am Acad Dermatol,2021
3. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations;Andrews;J Clin Epidemiol,2013
4. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength;Andrews;J Clin Epidemiol,2013
5. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group;Guyatt;J Clin Epidemiol,2016
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study;JAAD International;2024-12
2. Actinic keratosis: Current challenges and unanswered questions;Journal of the European Academy of Dermatology and Venereology;2024-06-26
3. Mobile health technologies in an interventional hybrid study on actinic keratosis: Results from an early phase randomized controlled trial investigating the safety and efficacy of a cytosolic phospholipase A2 inhibitor gel in photodamaged skin;Experimental Dermatology;2024-04
4. European consensus‐based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV‐induced dysplasia and field cancerization on behalf of European Association of Dermato‐Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes);Journal of the European Academy of Dermatology and Venereology;2024-03-07
5. Pharmacokinetics, Safety, and Tolerability of a Single 5‐Day Treatment of Tirbanibulin Ointment 1% in 100 cm2: A Phase 1 Maximal‐Use Trial in Patients with Actinic Keratosis;Clinical Pharmacology in Drug Development;2024-01-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3